Chronic hepatitis B (CHB) infection affects 254 million people worldwide and led to 1.32 million deaths from cirrhosis and hepatocellular carcinoma (HCC) in 2024. Antiviral therapy can reduce the risk of complications, but viral biomarkers are ...